R. Escrig

Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels.

A. Díez-Pérez, B. Clotet, E. Negredo, 2015, The Journal of antimicrobial chemotherapy.

Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteers

R. Paredes, B. Clotet, D. Back, 2015, AIDS.

Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)

B. Clotet, J. Martinez-Picado, C. Brander, 2019, EClinicalMedicine.

Time-resolved diffused optical characterization of key tissue constituents of human bony prominence locations

Paola Taroni, Andrea Farina, Antonio Pifferi, 2015, European Conference on Biomedical Optics.

Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals

B. Clotet, J. Martinez-Picado, C. Brander, 2014, PloS one.

Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study).

B. Clotet, E. Negredo, J. Puig, 2014, The Journal of antimicrobial chemotherapy.

Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48‐week analysis of results from the PROTEST study

R. Paredes, D. Podzamczer, E. Poveda, 2017, HIV medicine.